Immusoft Corp., founded in 2009, is a pharmaceutical company dedicated to revolutionizing the treatment of genetic diseases through its proprietary immune system programming technology. The company's core mission is to harness the power of autologous cell therapy to create novel treatments that can address a wide range of genetic disorders. Immusoft's primary product involves programming B cells to produce therapeutic proteins within the patient's body, offering a potentially transformative approach to disease management. Their market focus includes rare genetic diseases and conditions that currently lack effective treatments.

Notable figures associated with Immusoft include its leadership team and a distinguished Scientific Advisory Board composed of experts in immunology and genetic research. The company has attracted significant investment from prominent venture capital firms and has achieved key milestones such as successful preclinical trials demonstrating the efficacy of their B cell programming technology. Immusoft's innovative approach has the potential to significantly impact the field of genetic disease treatment, offering hope to patients with conditions that have been historically difficult to manage.